1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi
Citalopram Hydrobromide
CAS: 59729-32-7
Molecular Formula: C20H22BrFN2O
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Names and Identifiers
| Name | Citalopram Hydrobromide |
| Synonyms | Citalopran HBr CITALOPRAM HBR Citalopram HBr Salt Citalopram Hydrobromide Citalopram Hydrobromide Tablets Citalopram hydrobromide solution 5-isobenzofurancarbonitrile,1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobr 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi 1-[3-(DIMETHYLAMINO)PROPYL]-1-(4-FLUOROPHENYL)-1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE HYDROBROMIDE 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide |
| CAS | 59729-32-7 |
| EINECS | 261-890-6 |
| InChI | InChI=1/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H |
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Physico-chemical Properties
| Molecular Formula | C20H22BrFN2O |
| Molar Mass | 405.3 |
| Melting Point | 182-188°C |
| Boling Point | 428.3°C at 760 mmHg |
| Flash Point | 9℃ |
| Solubility | H2O: soluble (sparingly) |
| Vapor Presure | 1.53E-07mmHg at 25°C |
| Appearance | powder |
| Color | White |
| Merck | 14,2318 |
| Storage Condition | 2-8°C |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| MDL | MFCD02101306 |
| Physical and Chemical Properties | Citalopram hydrobromide is a strong, selective serotonin uptake inhibitor with antidepressant effects. Of particular interest is the absence of inhibition of cholinergic muscarinic receptors, histamine receptors, and α-adrenergic receptors. If these receptors are inhibited, there will be many side effects caused by antidepressant drugs, such as dry mouth, sedation, postural hypotension and so on. citalopram hydrobromide was equally effective in patients with endogenous and non-endogenous depression. Its antidepressant effect is usually established after 2-4 weeks. Citalopram hydrobromide does not affect the cardiac conduction system and blood pressure. This is especially important for older patients. Citalopram hydrobromide also did not affect the blood, liver, and kidney systems. The rare side effects and most mild sedative properties of citalopram hydrobromide make it particularly suitable for long-term 1-stage therapy. Moreover, citalopram hydrobromide does not cause weight gain, nor does it enhance the effects of alcohol. |
| In vitro study | Citalopram (Lu 10-171), as a novel bicyclic phthalate derivative, is a potent inhibitor of neuronal 5-hydroxytryptamine (5-HT) uptake, but not of noradrenaline(NA) and dopamine(DA) there is no effect on the absorption of 5-HT, GABA, acetylcholine and morphine receptors. Its inhibitory effect on neuronal 5-HT absorption is very specific and effective, while the absorption mechanism of other neurotransmitter amines is not affected by this drug. Relative to apoptotic activity, Citalopram exerts a major effect on proliferation. It regulates the cell cycle by increasing cell proliferative potential and decreasing apoptotic activity. In the cell culture of osteoblasts, Citalopram can affect and change the expression of FGF, MSX and TGFB. |
| In vivo study | Citalopram had no cardiotoxic effects, even when animals were exposed to concentrations of Citalopram well above clinical therapeutic levels. In humans, metabolites of citalopram are also potent 5-HT uptake inhibitors and have no effect on noradrenaline(NA) uptake. In the body, its metabolite concentration is lower than that of citalopram itself. In rats, Citalopram (1-16 mg/kg) stimulates the flexor reflex of the spinal hindlimb. Citalopram can enhance 5-HT transmission, and its mechanism of action may be through effective inhibition of absorption without acting on postsynaptic 5-HT receptors. |
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Risk and Safety
| Risk Codes | R11 - Highly Flammable R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R39/23/24/25 - R22 - Harmful if swallowed |
| Safety Description | S7 - Keep container tightly closed. S16 - Keep away from sources of ignition. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S24/25 - Avoid contact with skin and eyes. |
| UN IDs | 3249 |
| WGK Germany | 3 |
| RTECS | NP6313500 |
| HS Code | 29329990 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Standard
Authoritative Data Verified Data
This product is (±)-1-[3-(dimethylamino) propyl] -l-(4-fluorophenyl)-1, 3-dihydro-5-isobenzofurancarbonitrile hydrobromide. Calculated as the dried product, the content of C20H21FN2O • HBr shall not be less than 99.0%.
Last Update：2024-01-02 23:10:35
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline powder; Odorless.
- This product is easily soluble in hot water, soluble in chloroform or methanol, slightly soluble in anhydrous ethanol or water, almost insoluble in anhydrous ether.
melting point
The melting point of this product (General 0612) is 185~188°C.
Last Update：2022-01-01 13:42:29
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Differential diagnosis
Authoritative Data Verified Data
- take an appropriate amount of this product, add water to dissolve, add potassium permanganate test solution Dropwise, and place it for a moment. The purplish red color fades and the solution turns light yellow.
- The infrared absorption spectrum of this product should be consistent with that of the reference product (General rule 0402).
- the product of the aqueous solution of the identification of bromide reaction (General 0301).
Last Update：2022-01-01 13:42:30
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Exam
Authoritative Data Verified Data
optical rotation
take this product, precision weighing, add methanol to dissolve and quantitative dilution to make a solution containing about 25mg per lml, according to the law (General 0621), the optical rotation should be from -0.20 ° to +0.20 °.
acidity
take 0.2g of this product, Add 10ml of water, shake to dissolve, according to the law (General 0631),pH value should be 4.5~6.5.
fluorine
take this product about 10 mg, precision weighing, according to the fluorine inspection method (General 0805) determination, fluorine content should be 4.2% ~ 5.2%.
Related substances
take an appropriate amount of this product, add the mobile phase to dissolve and dilute to make a solution containing about 1.25mg per 1 ml as a test solution; Take an appropriate amount for precision measurement, A solution containing about 2.5ug per 1 ml was prepared by quantitative dilution with mobile phase as a control solution; An additional citalopram hydrobromide control product of about 5mg was added with Potassium periodate 0.lg and glacial acetic acid 2ml, heated and refluxed in a water bath for 30 minutes, removed, cooled, added water 5ml, heated and boiled to make the solution fade, cooled, added 20% potassium hydroxide solution 3ml, and shaken, about 5ml of the supernatant was taken, and the mobile phase was diluted to 25ml, and the solution was used as the system applicable solution. According to high performance liquid chromatography (General rule 0512) test, octyl silane bonded silica gel was used as filler; 0.1% acetate buffer solution (lg of sodium acetate was taken, water was added to dissolve, triethylamine was added to dissolve 6ml, shake well, adjust pH value to 4.6 with glacial acetic acid, add water to 1000ml)-acetonitrile (80:20) as mobile phase; Detection wavelength was 239nm; Column temperature was 45°C. The system applicable solution 20u1 was injected into human liquid chromatograph, and the chromatogram was recorded. The separation degree of citalopram peak and degradation product peak (relative retention time is about 0.9) should be greater than 1.8. 20 u1 of the test solution and the control solution were respectively injected into the liquid chromatograph, and the chromatogram was recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 0.5 times (0.1%) of the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than 2.5 times (0.5%) of the main peak area of the control solution.
residual solvent
take about 0.3g of this product, weigh it precisely, put it in a 10ml headspace bottle, add 3ml of dimethyl sulfoxide precisely, shake it to make the solution, seal it, and use it as a test solution; another precision weighing methanol, ethanol, acetone, isopropanol, dichloromethane, n-hexane, ethyl acetate, Tetrahydrofuran, toluene and benzene each appropriate amount, and dimethyl sulfoxide quantitative dilution made each lml containing methanol 300ug, respectively, ethanol 500ug, acetone 500ug, isopropyl alcohol 500ug, dichloromethane 60ug, n-hexane 29ug, ethyl acetate 500ug, tetrahydrofuran 72ug, toluene 89ug and benzene 0.2ug mixed solution, take 3ml, in a 10ml headspace bottle, sealed, as a control solution. According to the determination method of residual solvent (General Principle 0861 second method), the capillary column with 6% cyanopropyl phenyl-94% dimethyl polysiloxane (DB624 or similar) as stationary liquid is used as the column; the inlet temperature is 200°C; The detector temperature is 250°C; The initial temperature is 45°C, which is maintained for 10 minutes, and the temperature is increased to 120°C at a rate of 20°C per minute for 3 minutes, the temperature was then raised to 200°C at a rate of 40°C per minute for 5 minutes; The headspace bottle equilibration temperature was 85°C and the equilibration time was 25 minutes. Take the reference solution into the headspace, the separation degree between the chromatographic peaks should meet the requirements. Then take the sample solution and the reference solution into the headspace respectively, record the chromatogram, calculate the peak area according to the external standard method, methanol, ethanol, acetone, isopropanol, dichloromethane, n-hexane, ethyl acetate, Tetrahydrofuran, the residual amount of toluene and benzene shall be in accordance with the regulations.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product, put it in a platinum crucible, and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 20 parts per million of heavy metal when examined by law (General rule 0821, Law II).
Last Update：2022-01-01 13:42:33
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Content determination
Authoritative Data Verified Data
take this product about 0.25g, precision weighing, add glacial acetic acid 10ml and acetic anhydride 50ml shake to dissolve. Potentiometric titration (General 0701), with perchloric acid titration solution (O.lmol/L) titration, and the results of the titration with blank test correction. Each 1 ml of perchloric acid titration solution (0.1 mol/ L) corresponds to 40.53mg of c20 h21fn2o-HBr.
Last Update：2022-01-01 13:42:31
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Category
Authoritative Data Verified Data
antidepressants.
Last Update：2022-01-01 13:42:32
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Storage
Authoritative Data Verified Data
sealed storage.
Last Update：2022-01-01 13:42:33
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi - Citalopram Hydrobromide Tablets
Authoritative Data Verified Data
This product contains citalopram hydrobromide according to citalopram (C20H21FN2O) calculation, should be the standard amount of 90.0%-410.0%.
trait
This product is a white tablet or film-coated tablet, white or white after removing the coating.
identification
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- This product shows the identification reaction of organic fluoride (General rule 0301).
- take an appropriate amount of the fine powder of this product, add water, shake, filter, and identify the filtrate of bromide (General rule 0301).
examination
- Related substances appropriate amount of fine powder of this product is taken, and the mobile phase is added to dissolve citalopram hydrobromide and dilute to prepare a solution containing about 1.25mg of citalopram hydrobromide per 1 ml, which is filtered and the filtrate is taken as the test solution; an appropriate amount was taken in a precise amount and quantitatively diluted with the mobile phase to prepare a solution containing about 2.5ug per 1 ml as a control solution. Another 5mg of citalopram hydrobromide was added with Potassium periodate 0.lg and glacial acetic acid 2ml, heated and refluxed in a water bath for 30 minutes, removed, cooled, added water 5ml, heated and boiled to make the solution fade, cooled, added 20% potassium hydroxide solution 3ml, and shaken, about 5ml of the supernatant was taken, and 20ml of the mobile phase was added to dilute, and the solution was used as the system applicable solution. Determination of related substances of citalopram hydrobromide. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.2% ) , the sum of each impurity peak area shall not be greater than 4 times (0.8%) of the main peak area of the control solution.
- Content uniformity take 1 tablet of this product, put it in a 200ml measuring flask, add appropriate amount of mobile phase, sonicate for 15 minutes to dissolve citalopram hydrobromide, let it cool, dilute it to the scale with mobile phase, shake well, filter it, the content of the continued filtrate shall be determined according to the method under the content determination item, and shall comply with the regulations (General rule 0941).
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 second method), water 900ml as the dissolution medium, the speed of 50 rpm, according to the law, after 30 minutes, the appropriate amount of the solution was filtered, and the filtrate was taken as the test solution, water was added for dissolution and quantitative dilution to prepare a solution containing about 20% citalopram per 1 ml as a control solution. Take the test solution and the reference solution, according to the method under the content determination, calculate the dissolution of each tablet. The limit is 80% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; With 0.1% acetate buffer solution (take sodium acetate lg, add water 800ml to dissolve, add triethylamine 6ml, shake, the pH value was adjusted to 4.6 with glacial acetic acid, and water was added to 1000ml)-acetonitrile (72:28) as mobile phase; The detection wavelength was 239nm. 20ul of the applicable solution for the system under the item of related substances is injected into the human liquid chromatograph, and the chromatogram is recorded. The separation degree of citalopram peak and degradation product peak (relative retention time is about 0.9) shall meet the requirements. The theoretical plate number is not less than 3000 based on the citalopram peak.
- determination Method: Take 20 tablets of this product, precise weighing, fine grinding, precise weighing to take an appropriate amount of fine powder (about 20mg equivalent to citalopram), put it in a 200ml measuring flask, and add an appropriate amount of mobile phase, dissolve citalopram hydrobromide by ultrasound, cool, dilute to scale with mobile phase, shake well, filter, take filtrate as test solution, inject 10u1 into liquid chromatograph, record chromatogram; another citalopram hydrobromide reference product was precision weighed, dissolved and quantitatively diluted with mobile phase to make citalopram O in about 1 ml. lmg solution, shake, the same method. According to the external standard method to calculate the peak area, the result is multiplied by 0.8004.
category
Same as citalopram hydrobromide.
specification
20mg (based on C20H21FN2O)
storage
sealed storage.
Last Update：2022-01-01 13:42:34
Supplier List
Spot supply
Product Name: Citalopram Visit Supplier Webpage Request for quotationCAS: 59729-32-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Citalopram Hydrobromide Request for quotation
CAS: 59729-32-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 59729-32-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Citalopram Hydrobromide Visit Supplier Webpage Request for quotationCAS: 59729-32-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Citalopram Visit Supplier Webpage Request for quotationCAS: 59729-32-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Citalopram Hydrobromide Request for quotation
CAS: 59729-32-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 59729-32-7
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple SpecificationsSpot supply
Product Name: Citalopram Hydrobromide Visit Supplier Webpage Request for quotationCAS: 59729-32-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History